Sign In
Buy CCCC
$3.48
-0.180 (-4.92%)
At Close: Jul 31, 2026
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Inter
C4 Therapeutics Sees Unusually High Options Volume (NASDAQ:CCCC)
01:46am, Thursday, 18'th Dec 2025
C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders purchased 5,066 call options on the company. This represents an increase of
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss
06:27am, Wednesday, 26'th Nov 2025
C4 Therapeutics reported a Q3 GAAP EPS loss of –$0.44, missing estimates, but revenue of $11.23M beat expectations by $4.95M. CCCC's lead asset, cemsidomide, showed promising Phase 1 results in mult
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
07:00am, Tuesday, 25'th Nov 2025
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors
10:16am, Wednesday, 12'th Nov 2025
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide rang
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
09:26am, Thursday, 06'th Nov 2025
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.35 per share a year ago.
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 06'th Nov 2025
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceed
Brookstone Capital Management Purchases Shares of 29,325 C4 Therapeutics, Inc. $CCCC
04:03am, Thursday, 30'th Oct 2025
Brookstone Capital Management purchased a new stake in shares of C4 Therapeutics, Inc. (NASDAQ: CCCC) during the second quarter, according to its most recent filing with the Securities and Exchange Co
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
07:08am, Thursday, 16'th Oct 2025
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,
C4 Therapeutics, Inc. - Special Call
05:23am, Monday, 22'nd Sep 2025
C4 Therapeutics, Inc. - Special Call Company Participants Courtney Solberg - Senior Manager of Investor Relations Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Re
Why C4 Therapeutics Stock Crushed the Market on Monday
06:33pm, Monday, 15'th Sep 2025
C4 Therapeutics (CCCC 33.84%) was not only one of the better-performing healthcare stocks on Monday, it was one of the big winners on the market, period. The company seemed to have a rocket strapped t
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
07:00am, Thursday, 04'th Sep 2025
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,
